Google DeepMind, Meta, and AI drug discovery startup Isomorphic Labs are jointly investing $300 million into a project to build a "virtual cell," a computational model that researchers could use to understand disease mechanisms and accelerate drug development. The initiative is led by Biohub, a nonprofit biomedical research organization founded by Mark Zuckerberg and his wife, Priscilla Chan, according to reporting by Reuters and The Verge.
The virtual cell project aims to create a digital replica of cellular biology that scientists can manipulate and study. This would allow researchers to run experiments computationally rather than relying solely on laboratory work, potentially speeding up the process of identifying treatments for disease.
The partnership brings together three major players in artificial intelligence and biotechnology. Google DeepMind contributes expertise in machine learning and computational biology. Meta contributes AI infrastructure and engineering resources. Isomorphic Labs, founded by DeepMind researchers and focused on applying AI to drug discovery, contributes specialized knowledge in the biotech space.
Biohub itself was established by Zuckerberg and Chan to fund breakthrough biomedical research aimed at preventing, curing or managing disease. The $300 million investment represents a significant commitment to the virtual cell initiative, though the source material does not specify how the funding will be allocated across the three organizations or over what timeline.
The project reflects a broader trend of technology companies and AI researchers moving into drug discovery and biomedical research. Virtual cell modeling could reduce the time and cost of early-stage drug development by allowing researchers to test hypotheses computationally before moving to wet-lab experiments or clinical trials. The specific diseases or therapeutic areas targeted by this virtual cell initiative are not detailed in the available reporting.